← Leaderboards
Emily M. Henkle
Oregon Health & Science University
$2,455,143
Attributed
$2,455,143
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $682K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,455,143 · 2
By mechanism
R01$2,008,784 · 1
K01$446,359 · 1
Top collaborators
No co-investigators on record.
Most similar at Oregon Health & Science University
Same institution · by research overlap
- Kevin Loring Winthrop$7,724,085
- Gene Logan Bowman$2,137,822
- Kimberly Elizabeth Beatty$5,564,765
- Anupriya Agarwal$8,829,719
- Martina Mancini$7,671,398
Others in their field
Other Emerging Leaders on “Outcome Measure”
- Christopher Barnaby Nelson · University Of Melbourne$27,954,628
- James Dale Berry · Brigham And Women'S Hospital$25,163,692
- Abraham Aizer Brody · New York University School Of Medicine$23,525,790
- Tharick Pascoal · University Of Pittsburgh At Pittsburgh$21,289,866
- Priyamvada Acharya · Duke University$20,941,151
- Suzanne L Baker · University Of Pittsburgh At Pittsburgh$20,465,582
Research focus
Outcome MeasureOutcomes ResearchOlder PatientNon-Tuberculosis MycobacteriaLongitudinal AnalysisMycobacterium Avium ComplexCoughingCommon Terminology Criteria For Adverse EventsAntibioticsFatigueHealth Related Quality Of LifeInterestBeliefLung DiseasesClinical CareBronchiectasisClinical PracticeClinical TrialsCaringCharacteristicsDisabilityChronicChronic DiseasePathogen
Grant awards (6)
Patient reported outcomes in patients with nontuberculous mycobacterial pulmonary disease$682,008
R01 · FY2025 · HL · contact PI
Patient reported outcomes in patients with nontuberculous mycobacterial pulmonary disease$653,961
R01 · FY2024 · HL · contact PI
Patient reported outcomes in patients with nontuberculous mycobacterial pulmonary disease$672,815
R01 · FY2023 · HL · contact PI
Evaluating patient-reported outcomes for pulmonary nontuberculous mycobacterial disease$148,716
K01 · FY2022 · HL · contact PI
Evaluating patient-reported outcomes for pulmonary nontuberculous mycobacterial disease$149,098
K01 · FY2021 · HL · contact PI
Evaluating patient-reported outcomes for pulmonary nontuberculous mycobacterial disease$148,545
K01 · FY2020 · HL · contact PI